profit from every $100 of sales.
$0$100
Allogene Therapeutics
$1.06+1.92% today
-10.2% in 1 year
1-year low $1.041-year high $3.06
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Allogene Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $156,000 in 2022 to $0 in 2025, with -$191 million of profit last year.
SalesProfit
Allogene Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Allogene Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Allogene Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -336 | -314 | -257 | -207 | |
| -321 | -313 | -243 | -177 | |
| -340 | -327 | -258 | -191 | |
| -2.32 | -2.09 | -1.32 | -0.87 | |
| – | – | – | – | |
| -215,087.2% | -331,044.2% | -1,170,372.7% | – | |
| -218,214.1% | -344,489.5% | -1,170,863.6% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 822 | 643 | 549 | 416 |
| Cash | 62 | 83 | 75 | 52 |
| Total debt | 101 | 95 | 91 | 83 |
| Total liabilities | 155 | 131 | 127 | 123 |
| 667 | 512 | 422 | 293 | |
| 143 | 157 | 195 | 221 | |
| -34.5% | -42.6% | -39.6% | -39.9% | |
| -51.0% | -63.9% | -61.0% | -65.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -221 | -238 | -200 | -149 | |
| 5 | 2 | 1 | 0 | |
| -226 | -239 | -201 | -150 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 84 | 66 | 52 | 38 |
Valuation
- –
- –
- –
- 1.6×
- 16,693.4×
- –
- –
- -54.7%
- -70.1%
- 0.0%
Profitability
- 0.0%
- -1,170,372.7%
- -1,170,863.6%
- 0.0%
- -50.6%
- -43.7%
- -56.4%
- -43.9%
- -51.7%
- –
Growth
- −62.4%
- –
- +25.6%
- –
- +12.9%
Financial health
- –
- 0.29
- 20.5%
- -155.3×
- 9.65
- 9.65
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 948
Bottom 1%of 868
Bottom 1%of 985
What analysts expect
- Average price target
- $6.43
- Range
- $3.85 – $9.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.18 | -0.19 | +5.3% |
| Mar 12, 2026 | -0.17 | -0.25 | +32.0% |
| Nov 6, 2025 | -0.19 | -0.23 | +17.4% |
| Aug 13, 2025 | -0.23 | -0.28 | +17.9% |
| May 13, 2025 | -0.28 | -0.28 | +0.0% |
| Mar 13, 2025 | -0.28 | -0.34 | +17.6% |
| Nov 7, 2024 | -0.27 | -0.34 | +20.6% |
| Aug 7, 2024 | -0.32 | -0.35 | +8.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
56No pass
Philip Fisher
29No pass
Peter Lynch
15No pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
25No pass
Questions about Allogene Therapeutics
Is Allogene Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Allogene Therapeutics AI analysis
What does Allogene Therapeutics do?
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It is in Biotechnology.
Does Allogene Therapeutics pay a dividend?
No. Allogene Therapeutics does not pay a dividend at the moment.
Is Allogene Therapeutics stock halal?
No. Allogene Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 68% of its market value, at or above the 33% limit. How we check
How has Allogene Therapeutics stock done over the past year?
Down 10.2% over the past twelve months, to $1.06. It traded between $1.04 and $3.06 and is 65.4% below its high.
Who are Allogene Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Allogene Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.